Cargando…
Effect of Vorapaxar Alone and in Combination with Aspirin on Bleeding Time and Platelet Aggregation in Healthy Adult Subjects
The effect of the protease‐activated receptor‐1 (PAR‐1) antagonist vorapaxar on human bleeding time is not known. This was a randomized, two‐period, open‐label trial in healthy men (n = 31) and women (n = 5). In period 1, subjects received 81 mg aspirin q.d. or a vorapaxar regimen achieving steady‐s...
Autores principales: | Kraft, WK, Gilmartin, JH, Chappell, DL, Gheyas, F, Walker, BM, Nagalla, S, Naik, UP, Horrow, JC, Wrishko, RE, Zhang, S, Anderson, MS |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351335/ https://www.ncbi.nlm.nih.gov/pubmed/27304196 http://dx.doi.org/10.1111/cts.12405 |
Ejemplares similares
-
Vorapaxar: The missing link in antiplatelet therapy!
por: Nair, Abhijit S.
Publicado: (2017) -
Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States
por: Magnani, Giulia, et al.
Publicado: (2015) -
Clinical potential of vorapaxar in cardiovascular risk reduction in patients with atherosclerosis
por: Diehl, Philipp, et al.
Publicado: (2015) -
Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States
Publicado: (2015) -
Vorapaxar: A novel agent to be considered in the secondary prevention of myocardial infarction
por: Kehinde, Obamiro, et al.
Publicado: (2016)